Brought to you by 
Novartis Strengthens Immunotherapy Pipeline with Option, Collaboration and License Agreement with BeiGene for TIGIT Inhibitor Ociperlimab
21 Dec 2021
Executive Summary
Novartis signed an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company’s research and development activities in immuno-oncology.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis Strengthens Immunotherapy Pipeline with Option, Collaboration and License Agreement with BeiGene for TIGIT Inhibitor Ociperlimab
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice